Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP8B1 | Q9UNU6 | 13/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967805 | 1.00 | P2RY12 (0.61) | P2RY12MEN1KMT2ACYP8B1DPP4 | |
| SCHEMBL1968368 | 0.94 | P2RY12 (0.53) | P2RY12MEN1KMT2ACYP8B1DPP4 | |
| SCHEMBL1968365 | 0.94 | P2RY12 (0.53) | P2RY12MEN1KMT2ACYP8B1DPP4 | |
| SCHEMBL1968937 | 0.87 | P2RY12 (0.64) | P2RY12MEN1KMT2ACYP8B1 | |
| SCHEMBL1968143 | 0.87 | P2RY12 (0.64) | P2RY12MEN1KMT2ACYP8B1 | |
| SCHEMBL1968147 | 0.87 | P2RY12 (0.64) | P2RY12MEN1KMT2ACYP8B1 | |
| SCHEMBL12409511 | 0.85 | P2RY12 (0.70) | P2RY12MEN1KMT2ACYP8B1DPP4 | |
| SCHEMBL1968619 | 0.85 | P2RY12 (0.65) | P2RY12MEN1KMT2ACYP8B1 | |
| SCHEMBL13459935 | 0.84 | P2RY12 (0.71) | P2RY12MEN1KMT2ACYP8B1DPP4 | |
| SCHEMBL1968587 | 0.84 | P2RY12 (0.63) | P2RY12MEN1KMT2ACYP8B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | P2RY12 127/4885MEN1 849/4885KMT2A 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.